Suppr超能文献

可手术及晚期结直肠癌的化疗

Chemotherapy for operable and advanced colorectal cancer.

作者信息

Aschele Carlo, Bergamo Francesca, Lonardi Sara

机构信息

Medical Oncology Unit, E.O. Ospedali Galliera, 16128 Genova, Italy.

出版信息

Cancer Treat Rev. 2009 Oct;35(6):509-16. doi: 10.1016/j.ctrv.2009.04.003. Epub 2009 May 29.

Abstract

The majority of colorectal cancer patients receive chemotherapy either to palliate advanced unresectable disease or to reduce the risk of recurrence after radical surgery. Thanks to the improvements in systemic chemotherapy, in the last 20 years the median survival time for patients with unresectable metastatic disease has indeed progressively increased from less than 6 to almost 24 months and recurrences after radical surgery in patients with early-stage tumors have been halved. Although colorectal cancer incidence increase with aging, there is limited scientific evidence based on prospective clinical trials to guide the management of elderly colorectal cancer patients. In addition, aging is a continuum process making strict cut-off difficult to define and homogeneous subgroups hard to identify. There is significant heterogeneity also as regards comorbidities, overall physical ability, mental health and functional status. Specific guidelines for the medical treatment of elderly colorectal cancer patients are therefore difficult to draw. While fit patients are generally treated with adult protocols and frail individuals rarely receive chemotherapy, managing the intermediate vulnerable patients requires a careful balance between the biological and psycho-social costs of treatment, the aggressiveness of the tumor and its perception by the patient. In this review, the major achievements of chemotherapy in the treatment of colorectal cancer will be described and the available data addressing the extension of these chemotherapy programs to elderly patients will be discussed. Special emphasis will be given to the development of specific treatment strategies depending on the degree of disease aggressiveness. Empirical suggestions to adapt the chemotherapy programs developed for adult fit patients to subjects with various degrees of vulnerability and frailty will also be given along with practical indications for the use of specific chemotherapeutic agents in the presence of some common elderly-related comorbidities.

摘要

大多数结直肠癌患者接受化疗,目的要么是缓解晚期不可切除的疾病,要么是降低根治性手术后复发的风险。得益于全身化疗的进步,在过去20年中,不可切除转移性疾病患者的中位生存时间确实从不到6个月逐渐增加到近24个月,早期肿瘤患者根治性手术后的复发率减半。尽管结直肠癌发病率随年龄增长而增加,但基于前瞻性临床试验的科学证据有限,难以指导老年结直肠癌患者的管理。此外,衰老 是一个连续的过程,难以定义严格的界限,也难以识别同质亚组。在合并症、总体身体能力、心理健康和功能状态方面也存在显著异质性。因此,很难制定针对老年结直肠癌患者的具体治疗指南。健康的患者通常采用成人治疗方案,体弱的个体很少接受化疗,而管理中度脆弱的患者则需要在治疗的生物学和心理社会成本、肿瘤的侵袭性及其在患者中的认知之间仔细权衡。在这篇综述中,将描述化疗在结直肠癌治疗中的主要成就,并讨论将这些化疗方案扩展到老年患者的现有数据。将特别强调根据疾病侵袭程度制定特定的治疗策略。还将给出根据成人健康患者制定的化疗方案适应不同程度脆弱和体弱患者的经验性建议,以及在存在一些常见老年相关合并症时使用特定化疗药物的实际指导。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验